Corrigendum: Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

Guido Mannaioni, Fabio Lugoboni

Article Type

Corrigendum

Published

The authors wish to make the following corrections to their article: Mannaioni G, Lugoboni F. Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system. Drugs Context. 2023;12:2023-2-6. https://doi.org/10.7573/dic.2023-2-6

Read more

Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

Guido Mannaioni, Fabio Lugoboni

Article Type

Review

Published

This articles aims is to provide useful information and insights for the management of opioid agonist therapy by providing an overview that ranges from the characteristics of opioid use disorder patients to the macroscopic phenomena of social-health significance on a national scale, with a particular focus on the Italian territory.

Read more

Lurasidone for the treatment of schizophrenia in adult and paediatric populations

Teresa Guilera, Juan Pablo Chart Pascual, Maria del Carmen Blasco, Pilar Calvo Estopiñán, Rubén Asensio Piernas González, Isabel Ramírez Martínez, Cristóbal Rodríguez Moyano, Rita Prieto Pérez, Irene Gabarda-Inat, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasco

Article Type

Review

Published

In this review, the lurasidone development programme for adult and paediatric patients is described. In addition, the pharmacokinetic and pharmacodynamic characteristics of lurasidone are revisited, pivotal clinical studies conducted on both adults and children are summarized, and several clinical cases are also presented.

Read more

Propranolol for the management of behavioural and psychological symptoms of dementia

Rajesh R Tampi, Deena J Tampi, Syeda Arshiya Farheen, Sochima I Ochije, Pallavi Joshi

Article Type

Review

Published

There is some evidence that propranolol may benefit individuals with behavioural and psychological symptoms of dementia (BPSD). This article discusses three case series that assessed the use of propranolol for the management of BPSD. From these studies, it appears that propranolol improves BPSD and is well tolerated. In clinical practice, the routine use of propranolol among people with BPSD cannot be recommended at this time given the limited data. However, propranolol can be trialled among individuals with BPSD when symptoms have not responded adequately to other medications.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.